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Abstract 
The EuroBioBank (EBB) network (www.eurobiobank.org) is the first operating network of 
biobanks in Europe to provide human DNA, cell and tissue samples as a service to the 
scientific community conducting research on Rare Diseases (RDs). The EBB was 
established in 2001 to facilitate access to RD biospecimens and associated data; it 
obtained funding from the European Commission in 2002 (5th framework programme) and 
started operation in 2003. The set-up phase, during the EC funding period 2003-2006, 
established the basis for running the network; the following consolidation phase has seen 
the growth of the network through the joining of new partners, better network cohesion, 
improved coordination of activities, and the development of a quality control system.  
During this phase the network participated in the EC-funded TREAT-NMD programme and 
was involved in planning of the European Biobanking and Biomolecular Resources 
Research Infrastructure. Recently, EBB became a partner of RD-Connect, an FP7 EU 
program aimed at linking RD biobanks, registries and bioinformatics data. Within RD-
Connect, EBB contributes expertise, promotes high professional standards and best 
practices in RD biobanking, is implementing integration with RD patient registries and 
“omics” data, thus challenging the fragmentation of international cooperation on the field. 
 
Key words: Biobanking, biorepositories, rare diseases, biological samples, ELSI (Ethical 
and Legal Implications) 
 
 
Introduction 
 
The Organisation for Economic Co-Operation and Development (OECD) defines a biobank 
as “A collection of biological material and the associated data and information stored in an 
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organised system, for a population or a large subset of a population”.1 The collection of 
biological material and data for research and diagnosis has a long history in educational 
and medical institutions. In the past, biorepositories tended to be inconspicuous – the 
responsibility of individual research groups or institutions, and biospecimens were rarely 
shared with other laboratories. With recent technological advances, biorepositories are 
being opened up for new uses (when permitted by national regulations), and new 
biorepositories are being established as part of funded, but time-limited research projects; 
while information technology now enables the systematic linkage and tracking of samples 
and data, and has provided tools for access and analysis across vast sample sets and 
datasets. 
In the field of rare diseases (RDs) the number of available biospecimens is, in general, 
very limited. As a direct consequence of disease rarity, clinical trials are difficult to perform 
and so a limited number of treatments have been developed, while disease prognosis and 
natural history are poorly known, and patients with RDs do not receive the care and 
medical attention available to people with common diseases. Sharing material and data on 
RDs is essential for identifying disease-causing genes, studying pathological mechanisms, 
and developing treatments.  
In order to improve the accessibility of biospecimens and associated data on RDs, the 
EuroBioBank (EBB) network, involving 16 partners from 8 European countries (Belgium, 
France, Germany, Hungary, Italy, Malta, Slovenia and Spain), was established in 2001. 
The EBB obtained funding from the European Commission in 2002 (5th framework 
programme; EuroBioBank project QLRI-CT-2002- 02769) and started work in 2003.  
This report describes the development of the EuroBioBank network over the past decade, 
its achievements, and the major challenges it has already faced and expects to face in the 
future. 
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Set-up phase   
The EBB network (www.eurobiobank.org) was the first operating network of biobanks in 
Europe to provide human DNA, cell and tissue samples as a service to the scientific 
community conducting research on RDs. The idea of a network was first promoted by two 
patient organisations: the Association Française contre les Myopathies (AFM) and the 
European Organisation for RDs (EURORDIS). These organisations took cognisance of 
various circumstances and events which made it evident that a supranational biobank 
network was necessary, these included: letters from families and patients with RDs 
offering blood or other biological material to further RD research; scientific publications 
noting that difficulties in obtaining biological material from "informative" RD families were 
holding back research; the need to avoid wasting or loosing samples particularly when a 
research project wound down; the expansion of genomic research which raised hopes of 
earlier and more accurate diagnoses as well as more effective treatments; the creation of 
two biobanks – Généthon and Myobank-AFM (formerly Banque de Tissus pour la 
Recherche); and the establishment of French and European biobank networks for 
common diseases.  
A meeting to set up the EBB was held in Paris in 2001 with 16 founding partners (Table 1). 
At this time (1998-2002) the European 5th Framework Programme for Research and 
Development entitled "Quality of Life and Management of Living Resources" was soliciting 
applications for funding.  A proposal was submitted under action line 14.1 "Support for 
Research Infrastructures" and was accepted (Proposal N° QLRI-CT-2002-02769). A total 
of 1.22 M € was made available to the nascent EBB network by the European Commission 
for 36 months, starting 1st January 2003. The project period was subsequently extended 
for a further 3 months (to 31st March 2006). EURORDIS, a patient-driven European 
organisation for RDs, administered the EBB network from then to 2011.  
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The aims of the EBB network were to identify and locate repositories of biological material 
(DNA, tissues, cell cultures) pertaining to RDs, to harmonise and disseminate quality 
banking practices, to distribute quality material and associated data to scientific users, and 
to disseminate biobank-pertinent knowledge and know-how to the scientific community 
through specialised training courses, conferences, articles, and a website.  
Expected achievements included reorganization of existing bio-collections; improvement of 
medical and scientific collaboration in the field of RDs; and encouragement of research 
with concomitant development of new diagnostic tools and therapies for RDs. 
The project was organized into work packages (Table 2). The scientific coordinator was 
Dr. Cécile Jaeger of AFM, and the administrative coordinator was Dr. Fabrizia Bignami of 
EURORDIS. Dr. Jaeger retired from the project in 2005 and Dr. Hanns Lochmüller (then of 
the University of Munich, Germany; now at Newcastle University, UK) took over as 
scientific coordinator until 2012 (with annual re-elections from 2005 to 2011), when he 
resigned and Dr. Marina Mora of the Besta Neurological Institute, Milan, was elected by 
the EBB general assembly.  
 
Consolidation phase and TREAT-NMD 
When the EC-funded period expired (31st March 2006), EBB was kept going with funds 
contributed by each partner for 1 year in order to maintain the catalogue functional, meet 
annually and seek further funding. In 2007, EBB became part of the TREAT-NMD project 
in order to carry out biobanking for translational research in neuromuscular disorders (Fig. 
1). TREAT-NMD is a network of excellence funded by the EC (framework program 6, 
2007-2011) to provide an infrastructure (including biobanking) promoting the transition of 
promising new treatments for patients with neuromuscular diseases from preclinical 
development to clinical practice, and to establish best-practice care for patients with these 
diseases. This network, after EC funding expired, has developed from its European roots 
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to become a global organization, the TREAT-NMD Alliance, bringing together leading 
specialists, patient groups and industry representatives to ensure readiness for the clinical 
trials and therapies for the future, while promoting best practices today.  
In 2010, TREAT-NMD held a public consultation inviting all stakeholders to provide 
feedback on the impact of the TREAT-NMD activities and to provide guidance on the 
future priorities. The activity of the TREAT-NMD Network that received the highest 
recommendation – with over 90% indicating this as a top priority for the Network, was that 
of facilitating international collaborations to share data, experience and develop 
harmonised tools and protocols, and this included biobanking activities (http://www.treat-
nmd.eu/downloads/file/consultation/TREAT-NMD_Consultation_Document_Sept2010.pdf). 
From 2012, the Fondazione Telethon - partner of TREAT-NMD - took on the responsibility 
for EBB as a 3-year commitment within the newly established TREAT-NMD Alliance. 
Fondazione Telethon was already supporting genetic biobanks in Italy since 1993. In 
2008, Telethon had unified all its biobanks, creating the Telethon Network of Genetic 
Biobanks (TNGB) biobanknetwork.telethon.it, the first of this kind in Italy, with a virtual 
catalogue of biospecimens and associated data that presently lists more than 750 rare 
defects.2 In 2012, the natural progression has been to join the two Networks, EBB and 
TNGB. Of note, all neuromuscular biobanks of TNGB were already EBB members. A total 
of 10 additional partners have joined the EBB network since 2007 making to date a total of 
21 biobanks plus 4 non-biobank members (Table 1). Of note, biobanks from 3 additional 
countries (UK, Canada, Israel) have been accepted. 
From 2007 on the network only pays for joint services such as the website, the catalogue 
updating and annual meetings; while all the EBB partners had to cover their own costs 
regarding the operation of the biobanks either with institutional funding or with specific 
grants (such as Telethon grants supporting TNGB). 
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BBMRI-ERIC 
As part of TREAT-NMD, EBB collaborated with the European Biobanking and 
Biomolecular Resources Research Infrastructure (implemented under the European 
Research Infrastructure Consortium) (BBMRI-ERIC), in the planning of which it was 
represented by EURORDIS and by individual EBB biobanks that were full or associated 
partners in the BBMRI preparatory phase. EBB’s participation in BBMRI was somewhat 
uncertain at the beginning as the latter had no specific strategy for RDs and RD 
biobanking (BBMRI originally came from big population biobanking). However, BBMRI was 
open to the, argument, by the EBB coordinators, that biobanks with less than 100,000 
samples should be considered and might be extremely useful for research, particularly in 
RD. EBB eventually became part of the BBMRI Prototype in August 2009, and BBMRI and 
BBMRI-ERIC partner thanks to the FP7-funded project RD-Connect. BBMRI-ERIC is an 
infrastructure with sustainable funding from European member states covering a wide area 
of biobanks including bioresources for all diseases, irrespective of whether they are 
considered common or rare, as well as population-based cohort studies.3-5 However, it 
was acknowledged that RD research presents specific opportunities and challenges that 
requires specific procedures and distinguishes RD biobanking from other forms of 
biobanking.6,7 For this reason BBMRI-ERIC is considering the establishment of a common 
service for RD to specifically address issues related to RD biobanks. 
 
Governance 
The EuroBioBank Network Charter has been the constituting instrument of EBB from 
January 2006. It sets out the principles agreed upon by the partners of the network. In 
particular, the Charter recalls the ethical guidelines endorsed by the EBB Network, defines 
the organisation and governance of the EBB, establishes the benefits and duties attached 
to partnership, as well as the conditions of access to and withdrawal of partnership.  
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The EBB General Assembly is the decision-making and arbitration body of the Network 
that takes decisions on: (i) strategic orientations of EBB; (ii) establishment of an annual 
work plan and setting up of working groups; (iii) modifications and amendments to the EBB 
organisation and the Network Charter and appointment of the scientific coordinator; (iv) the 
EBB budget, management (partnership fees, investments, etc.) in collaboration with the 
finance manager responsible for the EBB account; (v) terms of use of the EBB name and 
logo; (vi) inclusion of new partners and exclusion of a partner; (vii) approval of each single 
sample request from private for-profit organizations.  
Membership 
The entry of new, European and non European, biobanks into the EBB network is 
encouraged. To this end, an evaluation procedure and specific assessment criteria have 
been established. Such criteria ensure adherence to minimum entry conditions that 
include: presence of collections of rare disease biological samples and their availability to 
the scientific community, a quality control system in place for the management of the 
biobank, with standard operating procedures (SOPs) regulating sample and data 
acquisition, and sample processing, storage, and distribution. The candidate biobanks 
should also adhere to Ethical, Legal and Social Implications (ELSI) principles and comply 
with the recommandations issued by the Oviedo Convention and the OECD Task Force on 
Biological Resource Centers,1,8 and with the national and European laws and regulations. 
 
Current access to samples  
Biobanks and biomaterial collections across the world can join EBB. The member biobank 
maintains the legal custodianship of samples, while the EBB acts as a clearing house or 
"virtual" biobank with its online catalogue and search engine for locating samples. 
Researchers from anywhere in the world who locate a sample of interest through the 
catalogue can directly contact the biobank holding the sample. Sample distribution is 
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governed by the conditions set out in the EBB charter and standardised material transfer 
agreements (MTAs). 
 
Achievements and recognition 
In addition to complying with workpackage tasks (Table 2), the EEB has prepared 29 
SOPs pertaining to sample and data acquisition, sample processing and storage, and 
sample distribution; has published (2005) a book on ethical and legal issues concerning 
international biobanking;9 has been awarded  the Newropeans Grand Prix 2004 for 
Research & Technology; has been cited as a “European model of coordination and of 
integration of Biological Resource Centres for the optimisation and improvement of the use 
of human biomaterial at European level”, in 2006, by IPTS (Institute for Prospective 
Technological Studies) / ESTO (European Science and Technology Observatory network). 
An immediate outcome of the effort to establish the EBB network, was the improved 
functioning of each EBB biobank member. Each biobank was forced to better organize the 
data to be included into the catalogue and to harmonize SOPs. This was facilitated by 
personnel training provided by the EBB organization, and by exchange of solutions within 
the network, including sharing rules for sample distribution and network acknowledgement 
in publications making use of EBB-supplied samples. Being part of the network, with 
specific agreed rights and duties under the network’s governance model, also contributed 
to improvement for the individual biobanks, e.g. systematically recording biobanking 
activities, adhering to standard operating procedures, and complying with ELSI principles.  
The Catalogue 
A great deal of work was devoted to drawing the EBB catalogue, in particular to define: 
catalogue content, vocabulary lists used for the minimum data set (normalized terms), how 
to update the catalogue, how to search in the catalogue. The partners agreed on the 
following minimum data set: (i) type of sample, (ii) classification of the disease based on 
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ICD-10 identifier and name, MIM number and name, (iii) number of families, (iv) number of 
patients, (v) anatomic origin, (vi) biobank contact. Since 2011 the catalogue was further 
implemented by the addition of an optional field for the ORPHA code, specially developed 
by Orphanet (www.orpha.net), as commonly used coding systems, like ICD or SNOMED 
CT codes, do not cover most of the rare disease names. 
The web-based EBB catalogue 
(http://www.eurobiobank.org/en/services/CatalogueHome.html) makes it possible to 
search for biological samples by type of biological material and disease. Of more than 
500000 samples stored in the EBB biobanks, 130000 were available on the catalogue at 
the end of 2013; 188400 new samples were collected from 2003-2013 and 73400 samples 
were distributed over the same period. On average 18800 samples (5700 neuromuscular 
disease samples, NMD) are collected and 7000 samples distributed (3000 NMD samples) 
each year (Fig. 2).  
Research Publications 
Up to December 2013, 255 original articles of research specifying the use of EBB 
biospecimens had been published (Fig. 3). 
DNA Samples were used mainly for diagnosis, for molecular-genetic studies to identify 
new disease-related genes, for studying human historical migrations, and to characterize 
epigenetic factors affecting disease phenotype.10-22 
Studies on EBB cell samples have been concerned with issues such as elucidation of 
biological pathways involved in diseases, in vitro characterization of muscle-immune 
interactions, molecular analysis of DNA methylation, chromatin structure, and epigenetic 
factors affecting disease expression. Cells were used in gene transfection and gene 
silencing experiments, in cell stimulation with growth factors and cytokines, to investigate 
exon skipping with antisense oligonucleotide treatment, to develop in vitro models for drug 
screening, to study mechanisms of muscular dystrophies with assays such as membrane 
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fusion, cell migration, immunochemistry, cell surface protein clustering, and viral-mediated 
protein expression.23-34 
Tissue samples were used to search for disease biomarkers, to define histopathological 
features of diseases, to verify protein expression and enzyme activity, and to obtain RNA 
for authentication of variants affecting RNA splicing.35-42 Serum and plasma samples were 
used in biomarker discovery and validation, in particular by the EC funded BIO-NMD 
project.43 
The recognition of EBB contribution has been usually recorded in the acknowledgments or 
in the material and methods sections of scientific publications. The users agree to 
acknowledge the role of the EBB facilities in the relevant publications by signing material 
transfer agreements (MTA) that are based on a model MTA agreed amongst EBB 
biobanks and their host institutions. The papers acknowledging the EBB contribution were 
determined either by direct communication of the EBB users, or by customized searches, 
e.g. through Google Scholar. 
EBB partners firmly recognize the importance of assessing the impact of bioresources and 
of facilitating their traceability. Indeed, some EBB partners (M. Filocamo, J-H Di Donato) 
are currently contributing to the development of BRIF (Bioresource Research Impact 
Factor), the tool to calculate the research impact of bioresources based on an algorithm 
and a unique digital resource identifier44 and, once the pilot studies will be completed, the 
EBB network is expected to contribute to BRIF implementation. In particular, to obtain 
BRIF, the EBB partners will submit to BRIF-Open Journal of Bioresources a marker paper 
which, by describing the main characteristics of their Biobank, will allow tracking 
bioresource use in the scientific literature45. 
Samples for research by for-profit organizations 
To develop better drugs for patients with RDs (translational biomedical research), 
academic organizations and infrastructures need to cooperate with the pharmaceutical 
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industry. In this regard, the network has been involved in a number of pharmaceutical 
company projects involving either searches for disease biomarkers or testing new 
therapeutic approaches. In particular, myoblasts and fibroblasts from Duchenne muscular 
dystrophy patients have been given to Prosensa to enable them to test exon-skipping 
approaches to therapy; cells from neuromuscular disease patients have been given to 
Santhera Pharmaceuticals to help them develop pharmaceutical products; and serum 
samples from muscular dystrophy patients have been provided to Summit and Pfizer for 
biomarker discovery and validation. 
 
Quality management system 
The setting up of common SOP’s for samples collection, processing and storage, the 
standardization of samples access policies, the adoption of a common minimum dataset 
and controlled terminologies necessary to build the EBB catalogue, were the first 
approach towards a quality control system. A further step was taken by the EBB network in 
2009 through the development of a satisfaction questionnaire to be sent to the users, for 
checking the quality of the services provided by the EBB biobanks. During years 2009-
2010, each partner sent the questionnaire to the users who, once had the document filled 
in, sent their feedback anonymously to EURORDIS. The evaluation of the questionnaires 
received revealed that the users were overall either “very satisfied” or “satisfied” with the 
service, and that EBB was seen as an essential service for scientists involved in research 
on RD who would otherwise have no access to these samples. Because of the low 
response rate (19/54) the value of the survey remained limited; however the users were 
satisfied with the provided service and in only 11% of cases encountered problems with 
the received samples; 84% of the responders confirmed that samples were essential for 
their experiments.  
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A reflexion process regarding quality system certification of the network and/or individual 
biobanks of the network began at the EBB meeting 2010. During the 9th annual meeting, 
the network moved forward with a tutorial to discuss the requirements to be fulfilled if a 
biobank wishes to assess its current quality management system (QMS), with a view to 
upgrade it and move toward ISO certification. A quality control (QC) questionnaire, listing 
the QMS requirements, was developed and used as the basis of the tutorial. Based on the 
QC questionnaire, the network planned further actions, feasible without additional funding, 
in order to acquire the ISO standards. These included implementation of self-assessment 
tools, harmonization of samples and data processing through common SOPs, and 
adoption of best practice guidelines and recommendations published by OECD, NCI, and 
ISBER. Certification and/or formal accreditation in conformity with the EU ISO standards 
remain the ultimate goal. 
 
Future developments and challenges 
The legal and regulatory frameworks that apply to this area are still fragmented, with 
variation of practice across the different areas of medical research.47 Biobanks have to live 
with these frameworks and practices which have raised a number of complex issues for 
society. For example, next generation sequencing techniques pose important issues in 
relation to the management of incidental findings.48,49 Although tools aimed at facilitating 
data and sample sharing are being developed48, privacy regulations and requirements 
vary between countries, rendering sample transfer between countries problematic. In 
addition, issues of communication between RD patient registries and RD biobanks still 
need to be addressed. A related problem is that different names are often used for a single 
disease creating difficulties when searching by disease. Other issues facing biobanking 
are lack of standards, agreed vocabulary, common data elements, and best practices for 
collecting data and processing samples. An accreditation and evaluation system to 
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recognise biobanks that provide high quality samples, and reward and acknowledge 
scientists who establish and maintain biobanks, should be established. In this regard, 
BRIF, the recently proposed quantitative parameter to assess the use of bioresources by 
the biomedical community, will represent a starting point for biobank recognition.44 Another 
important issue in RD biobanking is sustainability. Clearly, the pharmaceutical industry has 
little interest in funding small RD biobanks that contain and exchange limited numbers of 
samples. Specific funding for RD biobanks is therefore essential. Finally, very few 
biobanks are concerned solely with RD samples while some collections make material 
available only for specific types of studies and not others. In particular, biomaterials 
collected in natural history studies and clinical trials should be deposited in biobanks (with 
a broad consent allowing secondary use of the samples). Currently, most samples 
collected in these studies are “private” to these studies/investigators and cannot be shared 
(and often get destroyed at the end of the study). In this regard, the promotion of 
collaborations between biobanks and patient associations, in addition to helping gather 
more RD samples and associated data and make them available to researchers, could 
better address ethical and legal challenges because of the solidarity-based nature of the 
underlying agreements.50 
 
Recently, an application sent by the EBB scientific coordinator to RD-Connect’s executive 
committee, expressing EBB’s interest in becoming a partner of the RD-Connect platform, 
received formal approval. RD-Connect’s objective in biobanking is to provide access to RD 
biobanks that collect and provide standardised, quality-controlled biomaterials. In this 
regard, a dynamic, updated, searchable catalogue of biological samples linked to clinical 
data from patient registries and to patients’ “omics” data will represent RD-Connect’s major 
output.51 In this context EBB’s main aim is to contribute expertise to promote high 
professional standards and best practices in RD biobanking and implement the integration 
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with RD patient registries. The RD-Connect project was developed under IRDiRC 
(International Rare Disease Research Consortium), a European Commission and US 
National Institute of Health initiative to coordinate research funding on RDs, and RD-
Connect activities and policies are interconnected with those of IRDiRC. Therefore, EBB is 
providing work and expertise under the IRDiRC umbrella. Moreover, EBB partners are 
involved in IRDiRC biobanking related programs and activities, in particular through the 
IRDiRC working groups on biobanking (V. Karkagi, H. Lochmüller, M. Mora), and on 
registries and natural history of diseases (M. Posada) and the interdisciplinary science 
committee (H. Lochmüller). The EBB contribution to the challenges faced by biobanking is 
therefore extending beyond Europe and, hopefully, provide contributions to biobanking on 
a global level.  
 
Conclusions 
Over the past decade the scale of biobanking activities, in terms of the quantity of samples 
and data archived, the range of diseases covered, and the institutions involved, has 
expanded markedly. Biobanks are embedded in complex networks of research 
collaborations that span regions and countries. However, most European citizens have 
never heard of biobanks nor do they know of their importance in research on rare 
diseases. Furthermore, the legal and regulatory frameworks that apply to this area are 
fragmented. The EBB has long been the only network seeking to confront ethical, legal 
and social issues related to RD biobanking across European countries. In the absence of 
a unified regulatory framework, but by seeking professional guidance and applying 
professional values and culture, the EBB has been able to progress and contribute to the 
development of regulations as well as to establishing a basis for international cooperation 
in RD biobanking. Finally, EBB and biobanks in general need to overcome numerous 
challenges in order to achieve their full potential as essential aids to RD research. These 
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include: lack of harmonization; lack of biomaterial and data sharing; lack of recognition; 
and lack of sustainability. The EBB, with its long experience in international biobanking, 
will continue to be a key global resource for life sciences research, drug development and 
healthcare. 
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Figure Legends 
 
Fig. 1. Scheme illustrating interactions of EBB with European organisations and networks. 
Coordination of RD-Connect is lead by Hanns Lochmüller, who has also been the 
coordinator of TREAT-NMD; coordinator of the Telethon Network of Genetic Biobanks is 
Mirella Filocamo; coordinator of BBMRI during the preparatory phase was Kurt Zatloukal, 
now BBMRI-ERIC has a general director which is Jan-Eric Litton; EURORDIS is 
coordinated by a Board of Directors composed of elected RD patient organization 
representatives from countries around Europe (www.eurordis .org); IRDiRC is governed by 
an executive committee, three scientific committees and a number of working groups 
(www.irdirc.org).  
 
Fig. 2. Histograms showing (A) number of samples collected and distributed by the EBB 
network during period 2003-2013; and (B) type of biomaterials collected and distributed in 
total. 
 
Fig. 3. Histogram showing numbers of papers acknowledging EBB during the period 2004-
2013. 
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